Fabrazyme (agalsidase beta) received its initial FDA approval in April 2001 for the treatment of Fabry disease [1]. This approval was for patients who have a confirmed diagnosis of Fabry disease and have a clinically significant deficiency of alpha-galactosidase A enzyme activity [1].
When did Fabrazyme's FDA approval get suspended?
Fabrazyme's FDA approval was temporarily suspended in July 2010 due to manufacturing issues that led to a shortage of the drug [2]. These manufacturing problems, specifically related to viral contamination and reduced product yield, impacted the supply chain for both Fabrazyme and its counterpart, Replagal [3]. The suspension led to significant challenges for patients relying on the medication [3].
How did Fabrazyme return to the market after its suspension?
Following the suspension, Genzyme, the manufacturer of Fabrazyme, worked to address the manufacturing issues [2]. The company implemented corrective actions and invested in facility upgrades to ensure the safety and quality of the drug [2]. By November 2011, the FDA allowed Genzyme to resume full production and distribution of Fabrazyme, with expanded capacity and improved manufacturing processes [2].
What is the current status of Fabrazyme's FDA approval?
Fabrazyme remains FDA-approved for the treatment of Fabry disease [1]. The drug continues to be a vital therapeutic option for patients with this genetic disorder, providing enzyme replacement therapy to manage the accumulation of globotriaosylceramide in various tissues [1].
How does Fabrazyme work for Fabry disease?
Fabrazyme is an enzyme replacement therapy. It contains a recombinant form of the human enzyme alpha-galactosidase A [1]. In individuals with Fabry disease, this enzyme is deficient, leading to the buildup of a fatty substance called globotriaosylceramide within cells [1]. By administering Fabrazyme, the enzyme is supplied externally, helping to break down this accumulating substance and reduce its harmful effects on organs such as the kidneys, heart, and nervous system [1].
Are there other treatments for Fabry disease besides Fabrazyme?
Yes, other treatments are available for Fabry disease. Agalsidase alfa (Replagal) is another enzyme replacement therapy approved in some regions for Fabry disease [3]. Additionally, ongoing research is exploring other therapeutic strategies, including substrate reduction therapies and gene therapy [4].
When does the patent for Fabrazyme expire?
Information regarding specific patent expiration dates for Fabrazyme can be found on specialized patent tracking websites [5]. Patent protection is crucial for pharmaceutical companies, influencing market exclusivity and the potential for generic or biosimilar competition [5]. DrugPatentWatch.com provides detailed insights into patent lifecycles for various medications [5].